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A direct pathophysiological role of Familial Alzheimer’s Disease
(FAD)-associated Presenilin 1 (PS1) mutations in neuronal vul-
nerability remains a controversial matter. We evaluated the
relationship between PS1 and excitotoxicity in four different
experimental models of neurotoxicity by using primary neurons
from (i) transgenic (tg) mice overexpressing a human FAD-linked
PS1 variant (L286V mutation), (ii) tg mice overexpressing human
wild-type (wt) PS1, (iii) PS1 knockout mice, and (iv) wt mice in
which PS1 gene expression was knocked down by antisense
treatment. We found that primary neurons overexpressing mu-
tated PS1 showed an increased vulnerability to both excitotoxic
and hypoxic-hypoglycemic damage when compared with neu-
rons obtained from either mice overexpressing human wt PS1 or
in wt mice. In addition, reduced excitotoxic damage was ob-
tained in neurons in which PS1 expression was absent or
diminished. Data obtained in in vivo experimental models of
excitotoxicity partially supported the in vitro observations.
Accelerated neuronal death was demonstrated in the hippocam-
pus of mice overexpressing mutated PS1 after peripheral ad-
ministration of kainic acid in comparison with wt animals.
However, measurement of the infarct volume after middle
cerebral artery occlusion did not show significant difference
between the two animal groups. The results altogether suggest
that expression of FAD-linked PS1 variants increases the vulner-
ability of neurons to a specific type of damage in which exci-
totoxicity plays a relevant role. In addition, they support the
view that reduction of endogenous PS1 expression results in
neuroprotection.
A subset of early-onset cases of autosomal dominant familialAlzheimer’s disease (FAD) is caused by mutations in three
different loci: the amyloid precursor protein gene (1, 2) and the
Presenilin 1 (PS1) and Presenilin 2 (PS2) genes (3, 4). Of the
three loci, mutations in the PS1 gene are most frequent and
associated with early onset of the disease. PS1, widely expressed
throughout the central nervous system and in peripheral tissues,
is a multipass membrane protein localized predominantly in the
endoplasmic reticulum but also in the nuclear membrane and
coated transport vesicles (5–7). More recently, it has been
suggested that PS1 is constitutively expressed at the cell surface
of mammalian cells (8–10). On the basis of the predicted
structure, it has been proposed that PS proteins may function as
signal receptors, form channels, andyor participate in protein
trafficking (3). Yet, the physiological functions of PS1 in adult
life remain largely unknown.
Because Alzheimer’s disease (AD) is a neurodegenerative
disease characterized by the death of vulnerable neurons in
selective brain areas, much effort has been dedicated to find a
correlation between PS1 mutant isoforms and neuronal death.
Recently, Guo et al. (11) found that hippocampal neurons from
PS1 mutant knock-in mice show increased sensitivity to gluta-
mate-induced cell death. In addition, PS1 mutations have been
shown to increase the vulnerability of neural cells to apoptosis
induced by trophic factor withdrawal, b-amyloid, hyperosmotic
stress and aging, so as to suggest that PS1 mutations may lower
the threshold to neurotoxicity (11–15). The proposed mecha-
nism for such a role is that PS1 mutations contribute to disrupt
calcium homeostasis and increase free radical production (12)
andyor to influence intracellular signaling pathways (16, 17).
These results are apparently in contrast with the data of Bursz-
tajn et al. (18), who showed that overexpression in mouse cortical
neurons of human PS1 both in its normal and FAD-linked
isoform does not enhance apoptosis. Furthermore, down-
regulation of PS1 was associated with apoptosis of a series of
nonneuronal cell lines (19). Thus, a direct physiopathological
role of FAD-associated PS1 mutations in cellular vulnerability to
toxic stimuli is still a controversial matter.
Experimental Procedures
Animals. Generation of the transgenic (tg) lines overexpressing
human wild-type (wt) PS1 (PS1 wt tg) and FAD PS1 L286V (PS1
L286V tg) is described elsewhere, therein referred to as lines 195
and 198, respectively (20). In all studies, both lines were used as
homozygotes in a pure FVByN background. Non-tg littermates
of corresponding ageyweight were used as control animals and
referred to as wild-type (wt) mice. The PS1 knock-out mice used
in these experiments are described elsewhere (R.R., J. Huang, F.
Chen, C. Bergeron, Y. Liang, V. Nguyen, G. Wong, C. McKerlie,
M. Ikeda, G. Levesque, G. Yu, M. Nishimura, D.W., and P. Segh,
unpublished data). In short, these animals have a modification
of PS1 exon 6 such that neither intact transcript nor functional
protein is produced and is propagated on a mixed CD1 3
129ySvJ strain background. All of the experiments were carried
out in accordance with the National Institutes of Health guide
for the care and use of laboratory animals.
PS11/1, PS11/2, and PS12/2 Genotyping. Mouse tail genomic DNA
was purified by using standard methods followed by PCR
amplification. Primer sequences were as follows: 59-AGT TGG
TAG GAC CAC TTT GT-39 and 59-AGA CAC TTC CTC TTT
GCT AG-39 (endogenous mouse PS1) and 59-AGT TGG TAG
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GAC CAC TTT GT-39 and 59-ATG CCT GCT CTT TAC TGA
AG-39 (targeted allele). The wt allele product was 127 bp,
whereas the targeted allele product was 480 bp. The PCR
mixture contained 0.2 mM dNTP mixture, 2 mM MgCl2, 0.2 mM
of each of the primer sets, and 1.5 units Taq DNA polymerase.
Running conditions were as follows: 94°C for 30 s, followed by
35 cycles at 94°C for 30 s, 58°C for 30 s, and 72°C for 30 s.
Primary Neuronal Cultures. Mixed cortical cell and cerebellar
granule cell cultures were prepared from homozygotes PS1
L286V tg, PS1 wt tg, or from wt mice at 14–16 days of gestation
and at postnatal day 8, respectively, as previously described (21).
Pure cortical neurons were prepared from individual E16 em-
bryos derived from PS12/1 3 PS12/1 breeding pairs. Genotyping
was subsequently performed on tail DNA to identify PS11/1,
PS12/1, and PS12/2 embryos. All primary neuronal cultures
were used after 12–14 days in vitro.
In Vitro Neurotoxicity Assay. N-Methyl-D-aspartate (NMDA) (Sig-
ma) was added to culture medium in the absence or presence of
1 mM dizolcipine maleate (MK-801) (Sigma). For oxygen-
glucose deprivation (OGD), culture medium was exchanged with
deoxygenated glucose-free minimum essential medium (MEM).
Cultures were kept in an anaerobic chamber saturated with N2
for 60 min at 37°C. OGD was terminated by removal of the
cultures from the chamber and replacement of the medium with
oxygenated MEM supplemented with 1% horse serum. In both
experimental paradigms, neuronal viability was assessed 24 h
after NMDA addition or after removal from the anaerobic
chamber, as previously described (21). Briefly, in all mixed
neuron-glia experiments, neuronal cell death was expressed as
the percentage of total lactate dehydrogenase (LDH) release
elicited by 100 mM NMDA, a concentration that results in
maximal neuronal cell death. All values were corrected for basal
LDH release in each group. In both cerebellar and pure cortical
neuronal cultures, cell viability was determined by intravital
staining with fluorescein diacetate (15 mgyml) and propidium
iodide (80 mgyml) for 3 min at 25°C, and expressed as the
percentage of the total cell number.
Antisense Oligonucleotide Synthesis and Treatment. Phosphorothio-
ated PS1 oligodeoxynucleotides (ODNs) (PRIMM, Milan, Italy)
were 18 nt long and comprised the ATG codon corresponding to
the initiator methionine in the mouse gene. For each ODN,
acronimus, position relative to the ATG start codon, and
sequence were as follows: (i) PS1yAS-1 (antisense), 29 to 19,
59-CTC TGT CAT TGG AGC AGC-39; (ii) PS1ySENSE-1
(sense), 19 to 29, 59-GCT GCT CCA ATG ACA GAG-39; (iii)
PS1ySCR-1 (scramble), 19 to 29, 59-TCT CTG ACT GTG
AAG CCG-39; (iv) PS1yMIS-1 (mismatched), 29 to 1 9, 59-CTC
GTG CAT GTT AGC AGC-39; (v) PS1yAS-2 (antisense), 215
to 13, 59-CAT TGG AGC AGC TGG ACA-39; and (vi) PS1y
MIS-2 (mismatched) 215 to 13 59-CAT TGG AGC AGC TGT
CAT-39. ODN sequences exhibited no similarity to any other
known mammalian genes (BLAST search). As indicated, ODNs
(0.1, 0.3, 1, and 3 mM) were added to culture medium 2 h before
and during NMDA exposure.
Northern Blot Analysis. Total RNA was prepared from 5 3 106
cortical neurons treated as described, and 8- to 10-mg aliquots
were fractionated on 1.2% agarose-formaldehyde gels and trans-
ferred to nylon filters. A 2.0-kb XhoI fragment of a mouse cDNA
clone was used to measure PS1 mRNA transcripts. The 18S
rRNA DECAprobe template (Ambion, Austin, TX) was used to
generate an internal control so as to normalize for total RNA.
Hybridization was quantified by densitometry and expressed as
PS1y18S ratio.
Western Blot Analysis. The brain lysate (25 mg) was mixed with an
equal volume of 2% SDS, electrophoresed on 12% Tris-glycine
gels, and transferred to nitrocellulose. The C-terminal-specific
anti-PS1 polyclonal antibody (kind gift of N. Brindle, St. James
University Hospital, Leeds, U.K.) raised against residues 290–
304 of PS1 was used at a dilution of 1:5000, and proteins were
visualized by enhanced chemiluminescence (ECL, Amersham
Pharmacia) by using horse-radish peroxidase-conjugated goat
anti-rabbit secondary antibody.
Induction of Focal Cerebral Ischemia. Three-month-old (25–30 g)
PS1 L286V tg mice and non-tg littermates were subjected to
permanent occlusion of the left middle cerebral artery (MCA)
(20 tg and 20 wt) or of the left MCA plus the ipsilateral common
carotid artery (CCA) (17 tg and 18 wt) as previously described
(21). The body temperature was monitored and maintained at
37°C 6 1°C during surgery and during the immediate postop-
erative period until the animals recovered fully from anesthesia.
Twenty-four hours after combined MCA and CCA occlusion,
and 96 h after MCA occlusion only, brains were removed,
embedded in paraffin, and stained with cresyl violet. Eight
sections for each brain were digitized with a color video camera,
and total brain and infarct areas were measured on a blind basis,
by using an image analyzer system (Image Pro-Plus, Media
Cybernetics, Silver Spring, MD), as previously described (21).
Kainic Acid (KA)-Induced Neurodegeneration. Twenty-five wt and 24
PS1 L286V tg mice (27–30 g) were used. Seventeen wt and 17 tg
mice were given KA, 30 mgykg, i.p. Within this group, 14 mice
(7 wt and 7 tg) died during the first 24 h after the treatment.
Among survivors, 12 mice (6 wt and 6 tg) were killed at 3 days,
and 8 mice (4 wt and 4 tg) at 6 days. A separate group of 6
animals (3 wt and 3 tg) were given KA at 15 mgykg, i.p. They all
survived until day 3, when they were killed. Nine animals (5 wt
and 4 tg) were treated i.p. with saline and served as controls.
Mice behavior was monitored continuously for 6 h and rated
according to Racine’s scale (22). Serial coronal sections from
paraffin-embedded brain were cut at 5 mm, stained for hema-
toxylin-eosin, and examined for pathological changes. Profile
counting was confined to the anterior portion of the hippocam-
pus (bregma level 21.70 to 22.18 mm, figures 45–49 in Franklin
and Paxinos’ Atlas). One in every five serial sections was
analyzed by using a camera adapted to a Nikon microscope with
a 340 objective. The image processing and quantitative analysis
of histological data were performed by using IMAGE PRO-PLUS
software. Images were used for constructing an algorithm to
define ‘‘viable cells.’’ Viable cells were selected by size (diameter
greater than 7 mm) and color, automatically defined, encircled,
numbered, and counted. The mean profile numberymm2 was
obtained from at least 15 sections per each brain.
Data Analysis. Data in text and figures referred to studies in
cultures from wt and PS1 L286V tg mice, are expressed as
mean 6 SEM, and were analyzed by factorial ANOVA design.
Data relative to the study performed in cultures from PS11/1,
PS11/2, and PS12/2 embryos and in cultures from wt versus PS1
wt tg mice are expressed as mean and confidence limits, and
statistically analyzed by logistic regression for factorial design.
In in vivo studies, the infarct size was calculated with Cava-
lieri’s estimator of morphometric volume (23). A two-tailed
Student’s t test was used to determine statistical significance
between the wt and PS1 L286V tg mice. P , 0.05 was considered
statistically significant. ‘‘Non-responder’’ rate, defined as in ref.
21 was compared by using Fisher’s exact test. KA data were
expressed as the percentage of control and analyzed by ANOVA
with Student’s t test for simple comparison.










Relationship Between PS1 and Excitotoxicity in Primary Neurons from
tg Mice. Primary cortical cultures were established from human
PS1 L286V tg and wt embryos at E16 and maintained in vitro for
12–14 days before experimental use. During this period, no overt
difference in rate of maturation and differentiation was noted in
the two neuronal cultures (data not shown). As shown in Fig. 1A,
neurons overexpressing L286V PS1 showed a significant increase
in their sensitivity to NMDA-induced cell death, as demon-
strated by a leftward shift in the NMDA dose-response curve. At
the concentration of 3 mM, NMDA induced less than 10%
neuronal death (percentage of maximal cell death induced by
100 mM NMDA) in wt but almost 30% in the PS1 L286V tg
mice-derived cultures. A similar pattern of results was found by
using NMDA concentrations of 7.5 mM and 15 mM.
Exposure of cerebellar granule cells from wt mice to concen-
trations of NMDA ranging from 10 mM to 500 mM resulted in
a concentration-dependent cell death (Fig. 1B). Neurons from
PS1 L286V tg mice were significantly more sensitive to NMDA
treatment than their wt counterpart. In particular, concentra-
tions of NMDA that were below those required to cause
neuronal death in cerebellar cultures from wt mice (i.e., 100 mM)
were almost maximally neurotoxic in cultures overexpressing
mutated PS1.
The increased sensitivity of neurons from PS1 L286V tg mice
to excitatory amino acid-associated neuronal death was con-
firmed in the OGD paradigm (24). As shown in Fig. 1C,
cerebellar granule cells from PS1 L286V tg mice were signifi-
cantly more vulnerable (3-fold difference) to OGD than cells
from wt mice (20% and 60% over the corresponding basal value,
respectively). To dissect the contribution of human PS1 overex-
pression per se in our experimental setting, a parallel study was
then performed in cerebellar granule cells from PS1 wt tg mice
and FVByN non-tg littermates. No significantly different re-
sponse to NMDA-induced toxicity could be observed at con-
centrations ranging from 10 to 500 mM between the two exper-
imental groups. As shown in Fig. 2 Inset, PS1 wt and PS1 L286V
tg mice overexpress the human protein at comparable levels,
with a human vs. murine protein ratio of about 1.
Neurodegeneration in PS1 tg Mice After in Vivo Experimental Models
of Excitotoxicity. We then evaluated whether expression of a
FAD-associated PS1 gene mutation was able to affect neuronal
sensitivity to excitotoxicity in vivo. The wt and PS1 L286V tg
mice were treated with either two different doses of KA, 15 and
30 mgykg i.p. or saline. In animals treated with KA 15 mgykg,
only sporadic seizures were observed and the behavioral changes
consisting mainly of wet dog shakes, whereas administration of
30 mgykg induced convulsions in most animals. Treatment with
30 mgykg KA resulted in a comparable behavioral pattern in
both wt and PS1 L286V tg mice (data not shown). Both strains
Fig. 1. Effect of PS1 FAD mutation on in vitro excitotoxicity. (A) Primary cortical neurons from wt (open bars) or PS1 L286V tg (filled bars) mice were exposed
to increasing concentrations of NMDA, as indicated. Cell death was quantified by measuring the release of LDH enzyme in the culture media and was expressed
as the percentage of total LDH release elicited by 100 mM NMDA. (B) Primary cerebellar neurons from wt (open bars) or PS1 L286V tg (filled bars) mice were
exposed to increasing concentrations of NMDA, as indicated. Cell death was quantified by determining intravital staining with fluorescein diacetate and
propidium iodide and was expressed as the percentage of dead cells over total cell number. (C) Primary cerebellar neurons from wt (open bars) or PS1 L286V
tg (filled bars) mice were subjected to OGD for 1 h. Neuronal viability was assessed 24 h later by intravital staining with fluorescein diacetate and propidium
iodide. Data are expressed as the percentage of dead cells over total cell number. Numbers represent mean 6 SEM of at least six different experiments, run in
triplicate, each from different cell preparations. **, P , 0.01, and *, P , 0.05, vs. the corresponding values of wt group.
Fig. 2. Effect of human PS1 wt overexpression on in vitro NMDA-induced
neurotoxicity. Primary cerebellar neurons from wt mice (open bars) or human
PS1 wt overexpressing mice (filled bars) were exposed to increasing concen-
trations of NMDA, as indicated. Cell death was measured by intravital staining
with fluorescein diacetate and propidium iodide and was expressed as the
percentage of dead cells over total cell number. Where indicated, MK-801 was
added to the culture media 10 min before NMDA. Values are expressed as
mean and confidence limits and are from nine separate cell preparations with
each point run at least in quintuplicate. (Inset) Representative Western blot
analysis of PS1 protein levels in cerebellar extracts from wt mice and mice
overexpressing human wt (PS1 wt) or mutated (L286V) PS1. The C-terminal
fragment of both human (h) and mouse (m) PS1 protein was detected with an
anti-PS1 antibody. The calculated apparent molecular mass was 21 kDa and 20
kDa for human and mouse PS1 fragments, respectively.
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displayed a mortality rate of 41%. At 3 days after injection, the
lower KA dose produced minor histological damage whereas the
higher dose led to selective hippocampal cell loss in the CA3
subregion of both wt and PS1 L286V mice. We found tg mice to
be more sensitive to KA-induced neurodegeneration. Fig. 3
shows representative stainings of coronal brain sections from wt
(Fig. 3 A and C) and tg mice (Fig. 3 B and D) treated with saline
(Fig. 3 A and B) or 30 mgykg KA (Fig. 3 C and D), killed 3 days
after the injection. The degree of KA-induced lesion in the
different experimental groups was estimated by computer-
assisted measurement of profile counts as an unbiased index of
cell number, and shown in Fig. 3E. At 3 days, the percentage of
surviving neurons in the CA3 hippocampal region was about
70% and 45% of the corresponding saline-treated groups, in wt
and tg mice, respectively. At longer time points, i.e., 6 days, the
number of CA3-surviving neurons was similar in both experi-
mental groups (50% and 42% for wt and tg mice, respectively).
When focal cerebral ischemia was used as in vivo model of
neurodegeneration associated with excitotoxicity, we did not
observe significant differences in the responsiveness to the injury
in PS1 L286V tg mice compared with wt animals. The wt and tg
mice were subjected to two different paradigms of focal cerebral
ischemia in the territory of the MCA. We used both the
‘‘tandem’’ occlusion model (MCA plus CCA occlusion, 20
animals for each group), which produces larger infarct volumes,
and the single MCA occlusion model (18 wt and 17 PS1 L286V
tg mice), which results in smaller brain damage. After MCA 1
CCA occlusion, the infarct volumes were 26.0 6 1.9 mm3 and
29.9 6 2.3 mm3 (18.9 6 1.3% and 21.2 6 1.6% of ipsilateral
hemisphere) for wt and PS1 L286V tg mice, respectively. After
single MCA occlusion, lesion volumes were 5.6 6 0.6 mm3 and
6.8 6 0.8 mm3 (9.5 6 1.1% and 11.1 6 1.2% of ipsilateral
hemisphere) for wt and PS1 L286V tg mice, respectively. No
difference was observed in ‘‘non-responders’’ rate (about 25%).
Relationship Between PS1 and Excitotoxicity in Primary Neurons from
PS1 Knockout Mice. Pure cortical neurons were established from
PS11/1, PS11/2, and PS12/2 single embryos at E16 and main-
tained in vitro for 12–13 days. During this period, there was no
obvious morphological difference in differentiation rate be-
tween neurons from the different genotypes (data not shown).
PS11/2 and PS12/2 neurons showed a significant reduction in
their sensitivity to NMDA-induced cell death compared with
PS11/1 (Fig. 4). At a concentration of 60 mM, NMDA induced
nearly 90% neuronal death in the wt neurons whereas only 42%
and 48% in the PS12/2 and PS11/2 genotypes, respectively. The
Fig. 3. Effect of KA injection on neuronal viability in hippocampi from wt and
PS1 tg mice. (Upper) Representative micrographs of CA3 hippocampal region
from wt FVByN (A and C) and PS1 L286V tg (B and D) mice treated with saline (A
andB)or30mgykgKA(CandD)andkilled3daysafter the lesion. (E)Quantitative
analysis of KA-induced cell loss in the CA3 and dentate gyrus (DG) hippocampal
region of wt FVByN and PS1 L286V tg mice treated with either 15 mgykg or 30
mgykg KA and killed after 3 days (3d) or 6 days (6d), as indicated. Viable cells were
evaluated by estimating the mean profile number per mm2. Data are expressed
as the percent of the corresponding control values (black bar) and represent the
mean 6 SEM of at least 15 sections per each brain. Absolute values were 7.5 6
0.9 3 105 and 6.9 6 1.3 3 105 profile number per mm2 in dentate gyrus of wt and
PS1 tg mice, respectively, and 2.1 6 0.4 3 105 and 2.5 6 0.5 3 105 profile number
per mm2 in CA3 region of wt and PS1 tg mice, respectively. *, P , 0.05 vs. the
corresponding values of wt group.
Fig. 4. NMDA-induced neurotoxicity in primary cortical neurons from
PS11/1, PS11/2, and PS12/2 mice. Primary neurons from single embryos were
exposed to increasing concentrations of NMDA, as indicated. MK-801 (1 mM)
was added to the culture media 10 min before NMDA. Cell death was quan-
tified by intravital staining with fluorescein diacetate and propidium iodide
and expressed as the percentage of dead cells over total cell number. Values
are expressed as mean and confidence limits. P , 0.01 PS11/1 vs. PS11/2, P ,
0.01 PS11/1 vs. PS12/2. n, Number of cell preparations.









reduced sensitivity to NMDA was less apparent but still statis-
tically significant at maximally effective concentrations of the
excitotoxin. MK-801 (1 mM) completely reversed NMDA-
induced toxicity in all different genotypes.
Relationship Between PS1 and Excitotoxicity in Primary Neurons with
Reduced PS1 Gene Expression. Two 18-mer antisense ODNs com-
plementary to sequences flanking the initiation codon of the
mouse PS1 gene, PS1yAS-1 (29 to 19) and PS1yAS-2 (215 to
13), were individually added to the culture media of 12-day in
vitro cortical neurons, 2 h before and during NMDA treatment.
Incubation of neurons with 15 mM NMDA resulted in about 60%
of total LDH release in antisense-untreated cells. When cells
were pretreated with different concentrations of PS1yAS-1, a
dose-dependent reduction in NMDA-induced cell death was
observed (Fig. 5A). Maximal inhibition (250%) was found by
using 3 mM PS1yAS-1. At the same concentration, correspond-
ing sense (PS1ySENSE-1), scrambled (PS1ySCR-1), and mis-
matched (PS1yMIS-1) ODNs were devoid of effect. Under
similar experimental conditions, 3 mM PS1yAS-2, but not its
mismatched version (PS-1yMIS-2), prevented NMDA-induced
neuronal loss (250%). Both ODNs did not affect cell viability
per se (data not shown). A correlation was established between
ODN treatment and PS1 mRNA levels. Exposure of cortical
neurons to NMDA resulted in a concentration-dependent in-
crease of PS1 mRNA levels. Fig. 5B shows the results obtained
by measuring the effects of 30 mM NMDA on PS1 mRNA levels
in cell cultures either untreated or pretreated with 3 mM
PS1yAS-1 and PS1ySENSE-1. In untreated cells, 30 mM NMDA
induced a 2-fold increase in PS1 mRNA levels, detectable within
1 h, which was prevented by 1 mM MK-801, PS1yAS-1 ODN, but
not PS1ySENSE-1. Comparable inhibitory effects were obtained
with PS1yAS-2, but not with PS1yMIS-2, PS1yMIS-1, and
PS1ySCR-1 (data not shown).
Discussion
The first indication that PSs may regulate apoptotic cell death
emerged from a functional screening for cDNAs that could
rescue T cell receptor-induced apoptosis in a mouse T cell
hybridoma (25). Subsequent studies further indicated that both
PS1 and PS2 might participate in neuronal apoptosis (12, 13,
26–28). Recent work in hippocampal neurons derived from mice
generated by knock-in of a FAD-linked PS1 mutation also
supported this hypothesis (29). Finally, direct in vivo evidence for
a role of PS1 in neurodegeneration came from quantitative
stereological analysis, revealing a significant decrease in the
frontal cortex and hippocampal CA1 fields of aged mice ex-
pressing human FAD-linked variants compared with mice ex-
pressing wt PS1 (14).
In the present study, we found that neurons from PS1 L286V
tg mice have a significant increase in their sensitivity to excito-
toxicity. This phenomenon was observed in three different in
vitro experimental models, i.e., (i) cortical neurons exposed to
NMDA, (ii) cerebellar granule cells exposed to NMDA, and (iii)
cerebellar granule cells exposed to OGD. Because primary
cultures of cerebellar granule cells are 95–98% neuronal in
nature, it is reasonable to infer that the putative factor(s)
responsible for the PS1 mutation-related hypersensitivity to
excitotoxicity is constitutively expressed in neuronal cells. Based
on an extensive analysis of the sensitivity to excitotoxic death in
primary neurons from a transgenic line overexpressing wt human
PS1 at levels comparable to those of the PS1 L286V line, we
could rule out the possibility that human PS1 overexpression per
se could contribute to such effects.
Our in vivo data support the concept that expression of mutant
PS1 lowers the threshold to excitotoxicity. In line with recent
findings (11), we found PS1 L286V tg mice were more sensitive
to peripheral administration of KA than wt mice. This effect was
particularly evident at 3 days after the treatment but disappeared
at 6 days, suggesting that the FAD-linked PS1 mutation accel-
erates the neurodegenerative process. However, when animals
were subjected to cerebral ischemia, no difference was found
between wt and PS1 L286V tg mice. The possibility that different
results might be seen at different time points after the lesion
cannot be completely ruled out. However, it should be noted that
the molecular mechanisms promoting neuronal cell death (i.e.,
apoptosis) in the permanent focal ischemia and KA experimen-
tal models are not superimposable (30, 31). It is also well known
that different mechanisms contribute to the neurodegeneration
associated with animal models of permanent and transient
cerebral ischemia. In line with this concept, it was recently
reported that the extent of brain injury after ischemiay
reperfusion injury is indeed worsened in PS1 mutant knock-in
mice (32). Overall, our in vivo data suggest that predisposition to
excitotoxic damage induced by L286V PS1 mutation may not be
a generalized phenomenon, being affected by the type of neu-
rons that are involved, the extension of the lesion, and the
kinetics of the injury. The metabolic state and the intracellular
Fig. 5. Effects of PS1 ODN treatment on NMDA-induced neurotoxicity (A)
and PS1 mRNA expression (B) in primary cortical neurons from wt mice. (A)
Cortical neurons were exposed to increasing concentrations of different
ODNs, ranging from 0.1 mM to 3 mM, for 2 h before and during the NMDA
treatment. Cell death was quantified by measuring the release of LDH enzyme
and was expressed as the percentage of total LDH release elicited by 100 mM
NMDA. (B) Primary cortical neurons were exposed to different ODNs for 2 h
before the NMDA treatment. PS1 mRNA levels were measured by Northern
blot analysis 1 h after NMDA. Data represent mean 6 SEM of at least three
different experiments and are from three separate cell preparations. MK-801
was added to the culture media 10 min before NMDA. ODN sequence and
acronimus are reported in Experimental Procedures. *, P , 0.01 vs. NMDA
alone treated values.
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pathways triggered to induce neuronal death in a specific cell
phenotype may also contribute to different thresholds of vul-
nerability in the presence of mutated PS1. In this regard,
Bursztajn et al. (18) found that etoposide- and staurosporine-
induced apoptosis of cortical neurons is not affected by overex-
pression of either wt or mutated human PS1.
FAD-associated PS1 mutations are commonly believed to be
associated with a gain of function although the nature of the
putative function(s) is still under investigation. We addressed the
question of whether the PS1 mutation amplifies a physiological
function or, more specifically, whether wt PS1 is normally
involved in determining the neuronal threshold for excitotoxic-
ity. We therefore used primary neuronal cultures from PS12/2,
PS11/2, and PS11/1 and found that the absence or reduction of
PS1 results in a greater resistance of neurons to NMDA-induced
cell death. Because it has been shown that PS1, possibly via
Notch-1, is required for neuronal differentiation and neurite
outgrowth (33, 34), one may argue that the effects of lack of PS1
expression on threshold of vulnerability to NMDA are merely
due to delayed neuronal differentiation. In addition, this lower
vulnerability could be explained with the biased selection of a
subpopulation of cortical neurons that survive the severe devel-
opmental changes described in PS12/2 mice in vivo (35). At least
two observations argue against these possibilities. First, reduced
susceptibility to NMDA-induced cell death occurs not only in
PS12/2- but also in PS11/2-derived primary neurons, even
though the heterozygous mice do not show developmental
alterations. Second, greater resistance to excitotoxic-damage is
demonstrated also in neurons in which PS1 gene expression is
knocked-down after differentiation (antisense-treatment).
Our results support the view that endogenous PS1 is physio-
logically involved in determining the threshold for excitotoxicity
as well as playing an active role in the neurodegenerative process.
The proposed mechanisms for such a role include the possibility
that PS1 mutations may perturb calcium homeostasis and in-
crease free radical production in affected cells (12), andyor may
influence signaling pathways involving Aktyprotein kinase B
(PKB) (16), Jun kinase (17), or b catenin (28, 36). The molecular
mechanisms by which PS1, either physiologically or pathologi-
cally, when mutated, may interfere with neuronal survival pro-
grams therefore deserve further investigation.
We thank Dr. Catherine Strader for support throughout the study and
critically reviewing the manuscript, and Harsha Basudev and Ilaria
Barbieri for experimental assistance.
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